^
Association details:
| Biomarker: | KRAS G12S |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + milademetan (RAIN-32) (MDM2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
Published date:
05/12/2023
Excerpt:
The combination of milademetan and the MEK inhibitor trametinib was synergistic in growth inhibition of ECLC5-GLx (TRIM33-RET/MDM2amp), LUAD12c (METex14/KRASG12S/MDM2amp), SW1573 (KRASG12C,TP53 wildtype) and A549 (KRASG12S) cells, and in increasing expression of pro-apoptotic proteins PUMA and BIM.... Combined MDM2/MEK inhibition demonstrates efficacy across multiple patient-derived LUAD models harboring MDM2amp and concurrent oncogenic drivers.
DOI:
10.1016/j.jtho.2023.05.007
